Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03537547
Recruitment Status : Recruiting
First Posted : May 25, 2018
Last Update Posted : September 5, 2019
Sponsor:
Collaborator:
AssureRx Health, Inc.
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
This study aims to determine whether the GeneSight Psychotropic test can result in better treatment outcomes for patients with treatment-naive major depressive disorder

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Depression Depressive Disorder Depressive Episode Depression, Unipolar Other: GeneSight Psychotropic test Drug: FDA-approved antidepressant or antipsychotic treatment Phase 4

Detailed Description:

Major Depressive Disorder is a chronic psychiatric illness that leads to devastating consequences at the individual and societal levels. Today, the choice of treatment continues to be largely based on subjective factors, primarily the clinician and/or patient's preferences, as well as the individual's history of response to treatment, often tainted by recall bias. Psychiatric medication decisions are even more arbitrary when the subject in question has not had past treatment trials. This often leads to a trial and error process and an increasingly resistant disease with each failed trial. Early implementation of an objective tool designed for tailoring medication choice to an individual may prove highly beneficial in decreasing illness chronicity, individual suffering, and economic burden.

GeneSight Psychotropic test is a pharmacogenomic decision support tool, developed to help clinicians make informed, evidence-based decisions about proper drug selection. Therefore, we propose conducting a randomized, double blind, controlled trial to evaluate the impact of the GeneSight Psychotropic test to guide treatment decisions in patients with treatment-naïve (never having taken medication for depression) Major Depressive Disorder.

This study will involve 6 visits over about 24 weeks where participants will be randomized to have their study clinician have access to their pharmacogenetic report in order to make treatment decisions, or to not have access to their report for the first 12 weeks. At Visit 5, Week 12, all participants will receive a copy of their pharmacogenetics report and all clinicians will be unblinded to be able to use the results to guide treatment options for an additional 12 weeks.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants will be randomized to have their study clinician have access to their pharmacogenetic report (provide through the GeneSight Psychotropic tool) in order to make treatment decisions, or to not have access to their report for the first 12 weeks. At Visit 5, Week 12, all participants will receive a copy of their pharmacogenetics report and all clinicians will be unblinded for 'open label' to be able to use the results to guide treatment options for an additional 12 weeks.
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Coordinators at site are blinded, Sponsor and associates are unblinded.
Primary Purpose: Treatment
Official Title: Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder
Actual Study Start Date : May 4, 2018
Estimated Primary Completion Date : May 31, 2021
Estimated Study Completion Date : May 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: GeneSight Psychotropic test
Participants randomized to have their study clinician have access to their pharmacogenetic report (provided through the GeneSight Psychotropic tool) in order to make treatment decisions for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will continue to be able to use the results to guide treatment options for an additional 12 weeks.
Other: GeneSight Psychotropic test
GeneSight Psychotropic test, developed by AssureRx Health, is a genetic test that analyses pre-selected pharmacokinetics and pharmacodynamics genes and results in a composite phenotype and interpretive report, addressing both safety and efficacy of psychiatric medications.
Other Name: GeneSight test

Drug: FDA-approved antidepressant or antipsychotic treatment
Participant is treated with medications included in the GeneSight Psychotropic product.

Active Comparator: Treatment As Usual
Participants randomized to treatment as usual will receive treatment from study clinicians who do not have access to the participant's report for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will be unblinded to be able to use the results to guide treatment options for an additional 12 weeks.
Drug: FDA-approved antidepressant or antipsychotic treatment
Participant is treated with medications included in the GeneSight Psychotropic product.




Primary Outcome Measures :
  1. Hamilton Rating Scale for Depression change score- Week 8 [ Time Frame: Baseline to Week 8 ]
    17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity. Total range of the Hamilton Rating Scale for Depression is 0 to 52, with a greater score being an indication of more severe depressive symptoms.


Secondary Outcome Measures :
  1. Hamilton Rating Scale for Depression change score- Week 4 [ Time Frame: Baseline to end of week 4 ]
    17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity. Total range of the Hamilton Rating Scale for Depression is 0 to 52, with a greater score being an indication of more severe depressive symptoms.

  2. Hamilton Rating Scale for Depression change score- Week 12 [ Time Frame: Baseline to end of week 12 ]
    17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity. 17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity. Total range of the Hamilton Rating Scale for Depression is 0 to 52, with a greater score being an indication of more severe depressive symptoms.

  3. Hamilton Rating Scale for Depression change score- Week 24 [ Time Frame: Baseline to end of week 24 ]
    17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity. 17-item Hamilton Rating Scale for Depression (HAM-D17) to assess mean change in depressive symptoms severity. Total range of the Hamilton Rating Scale for Depression is 0 to 52, with a greater score being an indication of more severe depressive symptoms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adults 18-65 years of age
  2. Treatment-naïve major depressive disorder meeting Diagnostic and Statistical Manual 4th Edition (DSM-IV) criteria, without psychosis
  3. Total baseline score on the Quick Inventory Of Depressive Symptomatology Clinician-rated (QIDS-C16) and the Quick Inventory Of Depressive Symptomatology Self-Report (QIDS-SR16) rating scale ≥11
  4. Good command of the English language

Exclusion Criteria:

  1. Patients with a current diagnosis of schizophrenia
  2. Patients with a current diagnosis of schizoaffective disorder
  3. Patients with a current diagnosis of bipolar disorder (any type)
  4. Currently meeting DSM-IV criteria for significant substance use disorder (exception: nicotine use disorder)
  5. A diagnosis of personality disorder that may interfere with the patient's ability to improve on pharmacologic treatment, as determined by study investigator
  6. Patients currently receiving electroconvulsive therapy(ECT), deep brain stimulation (DBS) or transcranial magnetic stimulation (TMS) treatment
  7. History of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic or euthyroid for 6 months
  8. Significant unstable medical condition; life threatening disease; hepatic insufficiency; liver transplant recipient; cirrhosis of the liver; need for therapies that may obscure the results of treatment and/or of the study; malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications
  9. History of gastric bypass surgery
  10. Acute suicidal intention and/or in need of immediate hospitalization as judged by the investigator
  11. Active psychotic symptoms
  12. Currently in an inpatient facility
  13. History of prior pharmacogenomic testing
  14. Currently pregnant or lactating
  15. Inability to provide informed consent
  16. Any other factor that in the investigators' judgment may affect patient safety or compliance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03537547


Contacts
Layout table for location contacts
Contact: Britt Gott, MS 314-362-2463 gottb@wustl.edu
Contact: Araba Budu-Anguah, MPH 314-273-1921 abudu-anguah@wustl.edu

Locations
Layout table for location information
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Britt Gott, MS    314-362-2463    gottb@wustl.edu   
Principal Investigator: Charles R Conway, MD         
Sponsors and Collaborators
Washington University School of Medicine
AssureRx Health, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Charles Conway, MD Washington University School of Medicine

Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT03537547     History of Changes
Other Study ID Numbers: 201609109
First Posted: May 25, 2018    Key Record Dates
Last Update Posted: September 5, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Washington University School of Medicine:
treatment naive
major depression
pharmacotherapy
pharmacogenomic
genomics
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Depression
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Pathologic Processes
Behavioral Symptoms
Antipsychotic Agents
Antidepressive Agents
Psychotropic Drugs
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs